A detailed history of Td Asset Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Td Asset Management Inc holds 118,793 shares of NBIX stock, worth $14.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
118,793
Previous 140,267 15.31%
Holding current value
$14.9 Million
Previous $19.3 Million 29.18%
% of portfolio
0.01%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$114.58 - $153.15 $2.46 Million - $3.29 Million
-21,474 Reduced 15.31%
118,793 $13.7 Million
Q2 2024

Aug 02, 2024

SELL
$130.86 - $143.19 $414,433 - $453,482
-3,167 Reduced 2.21%
140,267 $19.3 Million
Q1 2024

May 08, 2024

BUY
$130.4 - $143.74 $5.11 Million - $5.64 Million
39,215 Added 37.63%
143,434 $19.8 Million
Q4 2023

Feb 12, 2024

BUY
$106.07 - $132.76 $5.15 Million - $6.44 Million
48,521 Added 87.11%
104,219 $13.7 Million
Q3 2023

Oct 27, 2023

BUY
$94.02 - $117.1 $1.91 Million - $2.38 Million
20,360 Added 57.62%
55,698 $6.27 Million
Q2 2023

Aug 09, 2023

SELL
$89.53 - $104.87 $139,487 - $163,387
-1,558 Reduced 4.22%
35,338 $3.33 Million
Q1 2023

May 10, 2023

SELL
$94.11 - $123.02 $118,766 - $155,251
-1,262 Reduced 3.31%
36,896 $3.73 Million
Q4 2022

Feb 06, 2023

SELL
$106.72 - $127.06 $10.6 Million - $12.6 Million
-99,494 Reduced 72.28%
38,158 $4.56 Million
Q3 2022

Nov 07, 2022

SELL
$92.03 - $107.81 $8.81 Million - $10.3 Million
-95,700 Reduced 41.01%
137,652 $14.1 Million
Q2 2022

Aug 04, 2022

SELL
$75.79 - $100.07 $2.89 Million - $3.81 Million
-38,082 Reduced 14.03%
233,352 $22.7 Million
Q1 2022

May 10, 2022

SELL
$72.45 - $94.81 $898,017 - $1.18 Million
-12,395 Reduced 4.37%
271,434 $25.4 Million
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $9.76 Million - $13 Million
122,495 Added 75.93%
283,829 $24.2 Million
Q3 2021

Nov 09, 2021

SELL
$86.18 - $99.03 $904,890 - $1.04 Million
-10,500 Reduced 6.11%
161,334 $15.5 Million
Q2 2021

Aug 11, 2021

SELL
$89.43 - $102.27 $2.08 Million - $2.38 Million
-23,251 Reduced 11.92%
171,834 $16 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $1.31 Million - $1.78 Million
14,930 Added 8.29%
195,085 $19 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $517,635 - $645,213
5,956 Added 3.42%
180,155 $17.3 Million
Q3 2020

Nov 10, 2020

BUY
$96.16 - $135.15 $721,296 - $1.01 Million
7,501 Added 4.5%
174,199 $16.8 Million
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $1.65 Million - $2.52 Million
19,341 Added 13.13%
166,698 $20.3 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $1.65 Million - $2.5 Million
-21,983 Reduced 12.98%
147,357 $12.8 Million
Q4 2019

Feb 11, 2020

BUY
$86.8 - $118.57 $1.09 Million - $1.48 Million
12,500 Added 7.97%
169,340 $18.2 Million
Q3 2019

Nov 07, 2019

BUY
$83.82 - $101.5 $6.15 Million - $7.45 Million
73,400 Added 87.97%
156,840 $14.1 Million
Q2 2019

Aug 01, 2019

SELL
$72.24 - $91.27 $195,048 - $246,429
-2,700 Reduced 3.13%
83,440 $7.05 Million
Q1 2019

May 08, 2019

SELL
$69.31 - $91.53 $755,409 - $997,585
-10,899 Reduced 11.23%
86,140 $7.59 Million
Q4 2018

Feb 01, 2019

SELL
$68.32 - $124.36 $2.73 Million - $4.97 Million
-40,000 Reduced 29.19%
97,039 $6.93 Million
Q3 2018

Nov 01, 2018

BUY
$98.88 - $125.85 $547,795 - $697,209
5,540 Added 4.21%
137,039 $16.8 Million
Q2 2018

Jul 31, 2018

BUY
$75.3 - $105.99 $158,130 - $222,579
2,100 Added 1.62%
131,499 $12.9 Million
Q1 2018

May 11, 2018

BUY
$75.88 - $92.43 $257,991 - $314,262
3,400 Added 2.7%
129,399 $10.7 Million
Q4 2017

Feb 02, 2018

SELL
$58.53 - $77.59 $1.52 Million - $2.02 Million
-26,031 Reduced 17.12%
125,999 $9.78 Million
Q3 2017

Nov 09, 2017

BUY
$47.97 - $61.28 $7.29 Million - $9.32 Million
152,030
152,030 $9.32 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.